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Abstract
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy in the developed world. EOC metastasis is
unique since malignant cells detach directly from the primary tumor site into the abdominal fluid and form multicellular
aggregates, called spheroids, that possess enhanced survival mechanisms while in suspension. As such, altered cell adhesion properties are paramount to EOC metastasis with cell detachment from the primary tumor, dissemination as spheroids,
and reattachment to peritoneal surfaces for secondary tumor formation. The ability for EOC cells to establish and maintain
cell–cell contacts in spheroids is critical for cell survival in suspension. Integrins are a family of cell adhesion receptors
that play a crucial role in cell–cell and cell-extracellular matrix interactions. These glycoprotein receptors regulate diverse
functions in tumor cells and are implicated in multiple steps of cancer progression. Altered integrin expression is detected
in numerous carcinomas, where they play a role in cell migration, invasion, and anchorage-independent survival. Like that
observed for other carcinomas, epithelial-mesenchymal transition (EMT) occurs during metastasis and integrins can function in this process as well. Herein, we provide a review of the evidence for integrin-mediated cell adhesion mechanisms
impacting steps of EOC metastasis. Taken together, targeting integrin function may represent a potential therapeutic strategy
to inhibit progression of advanced EOC.
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Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy in the developed world [1]. Most women
are diagnosed with advanced-stage disease with a 5-year
survival rate of less than 29%, since 80% of these cases present initially with metastasis [1, 2]. The delay in diagnosis
can be attributed to the wide range of non-specific symptoms
like abdominal fullness, vaginal bleeding and urinary symptoms thereby leading to a more advanced-stage before clinical assessment [3]. Factors for increased risk include early
age of menarche, and benign gynecological conditions such
as endometriosis, polycystic ovary and pelvic inflammatory
disease, whereas oral contraceptive use and tubal ligation
can decrease risk for EOC [1]. The current treatment plan
for patients with EOC in which tumors have spread beyond
the ovaries is maximal surgical cytoreduction with adjuvant
chemotherapy of combined carboplatin and paclitaxel [1].
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However, 75% of patients will have disease reoccurrence,
oftentimes acquiring chemotherapy resistance, ultimately
leading to a dire prognosis [1, 3].
EOC encompasses a heterogenous group of malignant
tumors that differ in prognosis, molecular pathology, and etiology. According to the World Health Organization (WHO),
EOC can be classified into seven histological subtypes: highgrade and low-grade serous, mucinous, endometrioid, clear
cell, Brenner, seromucinous and undifferentiated carcinomas
[4]. These histological subtypes can be organized into two
major EOC groups where Type I consists of lower grade,
slow-proliferating carcinomas within serous, endometrioid,
mucinous and clear cell histological subtypes that likely
arise from benign ovarian lesions [4, 5]. Whereas Type II
tumors are typified as being more aggressive disease derived
from secretory fallopian tube epithelium, and present histologically as high-grade serous, mixed epithelial or undifferentiated carcinomas [5, 6]. High-grade serous ovarian cancer
(HGSOC) represents 75% of all cases and is characterized
by the near universal presence of TP53 tumor suppressor
gene mutations, commonly as observed as missense gain-offunction alterations, although deletions and nonsense lossof-function mutations have been identified, too [7, 8]. This
genetic alteration arises within an early tumor precursor cell
of the distal fallopian tube, called serous tubal intraepithelial
carcinoma (STIC) lesion; protein-stabilizing TP53 missense
mutations promote secretory epithelial cell survival and
cell–cell aggregation under anchorage independent growth
conditions [8]. HGSOC is associated with lower prevalent
but recurrent somatic mutations in NF1, BRCA1, BRCA2,
RB1 and CDK12 totalling 5–8% of tumors [1, 8].
Furthermore, advanced EOC is characterized by ascites
fluid accumulation within the peritoneal cavity [5]. The
impairment of lymphatic drainage and increased secretion of vascular endothelial growth factor (VEGF) leads
to enhanced vascular permeability [5]. The unique microenvironment within malignant EOC ascites consists of a
variety of non-tumor cell types, such as fibroblasts, mesothelial cells, immune cells and endothelial cells, as well as
acellular components, such as soluble extracellular matrix
(ECM), matrix-degrading enzymes, cytokines and growth
factors [9].
The ECM is an integral and dynamic non-cellular component within all tissues and functions to support cells and
maintain tissue homeostasis [9–11]. Normal ovarian ECM
is composed of a highly-ordered arrangement of collagen
fibers and proteoglycans, such as decorin and versican, to
provide structural integrity, and maintain interstitial pressure and hydration to tissue [9–11]. However, ECM stiffness is commonly increased in EOC tumors through the
activation of stromal fibroblasts and collagen remodeling
into thick fibrils in random orientation, which can combine
to increase tumorigenesis, cancer invasion and migration
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[10–12]. For example, decorin loss and upregulation of versican, fibronectin, tenascin-C, and tenascin-X are associated
with poor prognosis and overall survival in EOC [9, 12]. The
binding of various ECM ligands to integrins, which are glycoprotein receptors at the cell surface to promote adhesion,
regulate complex signaling events alone or in combination
with growth factor receptors [13, 14].
The interactions between the tumor cells and ECM
within the tumor microenvironment are crucial since their
dysregulation has been implicated in EOC progression [9,
13]. Therefore, integrin-mediated interactions and function
within the tumor micro-environment represents a potential
unique therapeutic strategy in EOC. In this review, we discuss the contributions of integrin-mediated cell adhesion in
the critical steps during intraperitoneal metastatic cascade
of EOC pathogenesis, including spheroid formation, epithelial-mesenchymal plasticity, and mesothelial attachment of
secondary tumors.

Integrin signalling
The integrins comprise a superfamily of cell adhesion receptors that recognize ECM and cell-surface ligands [15]. There
are 18 α-subunits and 8 β-subunits that assemble to create 24
functionally distinct transmembrane heterodimers. Integrins
are grouped according to their ligand-binding specificity:
collagen-binding integrins (α1β1, α2β1, α10β1, and α11β1),
laminin-binding integrins (α3β1, α6β1, α7β1, and α6β4),
leukocyte-integrins (α4β1, α9β1, α4β7, αEβ7,αLβ2, αMβ2,
αXβ2, and αDβ2) and arginine-glycine-aspartate (RGD)-recognizing integrins (α5β1, α8β1, αVβ1, αVβ3, αVβ5, αVβ6,
αVβ8, and αIIbβ3) [15] (Fig. 1a).
These receptor complexes have no enzymatic activity but
instead activate bidirectional signaling pathways [13, 15].
The affinity of integrin receptors for ECM components and
other ligands is tightly regulated by inside-out signaling [15]
(Fig. 1b). Integrin receptors maintain α and β subunit cytoplasmic tail association during their inactive stage, and cytoplasmic signals from associated G-protein coupled receptors
lead integrin β subunit phosphorylation within its cytoplasmic
domain for receptor activation [15, 16]. The integrin binding of cytoskeletal proteins such as talin, vinculin and ERM
(ezrin, radixin, and moesin) acts to regulate actin microfilaments of the cytoskeleton [15, 16]. In contrast, outside-in
signaling occurs through the clustering of integrin receptors at
the plasma membrane where ECM ligation transduces signals
intracellularly [15, 17] (Fig. 1b). Natural extracellular ligands
include several components of the ECM such as collagen,
laminin, fibronectin and vitronectin [13, 15]. Extracellular
ligand binding induces conformational changes in the integrin
receptor to allow intracellular tails of the β subunit to engage
with intracellular signaling molecules including focal adhesion
kinase (FAK), small GTPases Rho and Ras, and adaptors, such
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Fig. 1  Integrins are a superfamily of cell adhesion receptors that
recognize ECM and cell-surface ligands. They consist of 18 α-subunits and 8 β-subunits that assemble to create 24 functionally distinct
transmembrane heterodimers. a Integrins are grouped according to
their ligand-binding specificity: arginine-glycine-aspartate (RGD)recognizing integrins, laminin-binding integrins, collagen-binding
integrins and leukocyte-integrins. b Integrins take part in bidirectional signaling once the integrins move from a bent configuration to
an active form. During inside-out signaling, G-protein coupled receptors lead to integrin β subunit phosphorylation within the cytoplasmic
domain for receptor activation. The integrin binding of cytoskeletal
proteins such as talin, vinculin and ERM (ezrin, radixin, and moesin)

acts to regulate actin microfilaments of the cytoskeleton. Outside-in
signaling occurs through the clustering of integrin receptors at the
plasma membrane where ECM ligation transduces signals intracellularly. ECM binding with ligands such as collagen, laminin and
fibronectin induces conformational changes in the integrin receptor
to allow intracellular tails of the β subunit to engage with intracellular signaling molecules including focal adhesion kinase (FAK), small
GTPases Rho and Ras, and adaptors, such as Cas/Crk and paxillin.
Integrin acting alone or in complex with growth factors present in the
local microenvironment can regulate diverse tumor cell functions,
such as migration, invasion, adhesion and proliferation through the
activation of various signaling pathways. [created via biorender.com]

as Cas/Crk and paxillin [17]. These activated integrin-ECM
interactions lead to the formation of dynamic adhesion structures as small extensions from the plasma membrane called
podosomes [15, 16, 18]. After ECM ligation, integrins acting
alone or in complex with growth factors present in the local
microenvironment can regulate diverse tumor cell functions,
such as migration, invasion, adhesion and proliferation through
the activation of various signaling pathways [13, 15].

that cells within precursor lesions can be further stimulated
by local inflammatory cytokines, growth factors and hormones, such as transforming growth factor-beta (TGF-β)
and activin A present in follicular fluid that promote migration of STIC cells to the ovary [20–22]. The movement of
STIC lesions to the rich microenvironment provided by the
ovary is a critical step in the transition of STIC lesions to
HGSOC by attaching, invading and establishing a primary
tumor [1, 23–25]. This model has been supported by studies in which ovariectomies performed in mice harboring
precursor lesions results in reduced tumor formation and
intraperitoneal metastasis, emphasizing the importance of
the ovarian microenvironment for complete malignant progression [23, 26].
Unlike hematogenous routes involving intravasation and
extravasation where cancer cells must penetrate multiple

Implication of integrin function in EOC
metastasis
The primary site of origin for HGSOC is the secretory epithelium of the distal fallopian tube from precursor STIC
lesions [7, 19]. After TP53 mutations occur, it is postulated
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barriers, intraperitoneal dissemination is the primary means
of EOC metastasis, and is observed albeit less frequently
in colorectal, gastric and pancreatic cancers, also [5, 27,
28]. Despite the more passive nature of intraperitoneal dissemination, it leads to rapid disease progression, frequent
relapse, complications like bowel obstruction, and overall
poor prognosis [5, 6]. During advanced-stage EOC, metastatic cancer cells impair lymphatic drainage and secrete
VEGF that enhances vascular permeability and ascites fluid
accumulation in the peritoneal cavity [5, 29]. Ascites fluid
often contains EOC cells, as well as a highly heterogeneous
and variable mix of other cellular and acellular components
[5, 9]. Direct spread of EOC tumor cells into the peritoneal

Fig. 2  A schematic model of ovarian cancer dissemination and
the role of integrins in cancer metastasis. The primary site of origin for HGSOC is the secretory epithelial cells of the distal fallopian tube from precursor STIC lesions and the increase in L1CAM
and increased ligation of fibronectin to α5β1-integrin promotes cell
detachment. Detached EOC cells survive in hypoxic and anchorage-independent conditions by forming heterogenous multicellular
structures known as spheroids to avoid anoikis. Spheroid formation

13

Clinical & Experimental Metastasis (2022) 39:291–301

cavity is due to enhanced anchorage-independent tumor cell
survival that may be supported by altered cell–cell and cellECM functions of various integrins (Fig. 2).

Integrins in EOC spheroids
EOC cells that are bound for metastatic dissemination must
first detach from the primary tumor site. Proteolytic activity
by membrane type 1 matrix metalloproteinase (MT1-MMP,
or MMP14) is required in part for the initial detachment
of EOC cells from the primary ovarian tumor by cleaving
α3-integrin on cancer cells and contributing to decreased
cell adhesion [30]. Detached EOC cells survive in hypoxic

can be enhanced with the interaction of integrins with various ECM
proteins. Clustering of integrins such as α2β1 and α3β1 leads to the
loosening of intercellular adhesions between cells and contributes to
EMT-MET switching. The final step of EOC metastasis occurs when
spheroids penetrate mesothelial surfaces, and integrin-mediated degradation of the ECM within the basement membrane underlying the
peritoneum leads to secondary metastasis. [created by biorender.com]
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and anchorage-independent conditions by forming heterogeneous multicellular structures known as spheroids thereby
avoiding anoikis, which is a specific form of apoptosis triggered by the lack of attachment to other cells or ECM [5, 31,
32]. Spheroids further complicate the disease by exhibiting
decreased cell proliferation by accumulating in the G0/G1
phase of the cell cycle and becoming resistant to chemotherapeutic agents, such as paclitaxel and cisplatin [33,
34]. It is important to appreciate, however, that not all cells
within spheroids may have the same properties. For example, spheroids represent metastatic EOC cells that move in
a coordinated fashion, a process called collective migration.
This is driven by outer “leader” cells that direct migration
and enable the invasion of basement membrane, then “follower cells” that mediate actomyosin contraction allowing
for cellular movement [35, 36].
The first step of spheroid formation consists of cell–cell
interactions either directly or through ECM bridges. The
abundance of integrins available to cells within these multicellular aggregates may provide a major contribution to
spheroid formation and pro-survival signaling [37]. Doberstein et al. demonstrated that the loss of L1 cell adhesion
molecule (L1CAM) reduced the capacity for OVCAR8
cells to form spheroids, ultimately leading to cell death
[26]. Alternatively, L1CAM overexpression led to increased
spheroid formation in OVCAR8 cells as well as multiple
immortalized human fallopian tube epithelial cell lines [26].
L1CAM expression promotes the upregulation of fibronectin
and integrin subunits α5 and β1, which together promote
cell aggregation into spheroids yet detachment from the
primary tumor and tumorigenesis [26]. Fibronectin is abundant within the ascites and plays a critical role in spheroid
integrity [38, 39] by interacting with its canonical integrin
receptor α5β1 [40, 41]. For example, OVCAR5 spheroids
co-express of α5β1 integrin and fibronectin on the their surface [41]. The functional inhibition of β1-integrin using an
inhibitory antibody results in the disruption of EOC spheroids, whereas β1-integrin clustering and fibronectin activate
α5β1 heterodimer assembly to promote spheroid formation
[41].
Spheroid compaction into dense aggregates is critical for
tumorigenesis and related to their actomyosin contractile
capacity mediated by integrins and cadherins [39, 42]. A
positive correlation may exist between compact spheroid formation and tumorigenic capacity, as well as enhanced invasive capacity in EOC [42]. Sodek et al. demonstrated that
β1-integrin activation using an activating antibody 12G10
and ectopic β1-integrin upregulation enhanced more compact cell aggregation using SKOV3 and OVCAR3 cells, two
EOC cell lines that typically form less compact spheroids
[42]. Conversely, treating compact HEY cells spheroids with
a β1-integrin blocking antibody MAB13 led to spheroid disaggregation [42]. Casey and colleagues also demonstrated
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that treating OVCAR5 cells with a β1-integrin blocking antibody inhibits spheroid formation, while addition of exogenous fibronectin promoted EOC spheroid formation [41].
Similarly, laminin interactions with α6β1-integrins, and
collagen with α2β1-integrins, mediate spheroid formation
[41, 43]. In contrast, spheroid formation can be enhanced
in the presence of antibodies targeting α2, α4, α6 or αvβ3integrins, implicating these specific integrins may negatively
regulate spheroid formation [41].
Kellouche and colleagues identified αV-integrin and
vitronectin colocalization within multicellular aggregates
at intercellular sites suggesting a contribution in cell–cell
interactions [44]. They demonstrated through the use of antivitronectin, anti-αV-integrin, or the cyclic peptide cRGDfV,
blocked initial formation of IGROV1 spheroids [44]. The
blockade of αV-integrin decreased integrin-linked kinase
(ILK) activity resulting in reduced Akt phosphorylation
and increased cell cycle inhibitor p27kip1 expression [45].
αV-integrin can directly regulate ILK activity since antiαV-integrin inhibits ILK activity whereas ectopic ILK
overexpression rescues the effect of this blockade [45].
Anchorage-independent growth of IGROV1 spheroid cells
leads to a significant decrease in ERK1/2 phosphorylation
compared to adherent cells. Inhibition of ERK1/2 activation using MEK1/2 inhibitor U0126 in IGROV1 spheroids
decreases cell viability with increased PARP cleavage and
caspase-3 activity [46]. A role for integrins in this process
was demonstrated by Carduner et al. where increased anoikis
in IGROV1 spheroids due to αV-integrin silencing is associated with decreased ERK1/2 activation. This suggests
that αV-integrin promotes spheroid cell survival by inducing ERK-dependent pathways [46]. This association has
also been demonstrated in an anoikis-resistant population
of human intestinal carcinoma cells due to αVβ3-integrin
expression [47].
Cancer stem-like cells (CSC) may play a role in EOC
spheroid formation. CD90, also referred to as Thy-1, is a
glycoprotein typically mediating T-cell activation and neurite outgrowth [48, 49]. However, it has been identified as
a marker for CSC in gastric, lung, esophageal and liver
cancer [50–53], yet its expression is decreased in ovarian
cancer tissue and this lower expression of CD90 predicts
poor prognosis [51]. Furthermore, CD90 functions as a
tumor suppressor gene in ovarian cancer and the expression
of CD90 promotes anoikis and inhibits stemness properties
including sphere-forming ability [51]. In fact, Chen et al.
showed that exogenous CD90 decreases SKOV3 spheroid
formation and promotes apoptosis with increased cleaved
PARP expression [51]. Ectopic CD90 expression decreases
expression of canonical CSC markers CD133 and CD24,
and promoted mammalian/mechanistic target of rapamycin
(mTOR) phosphorylation and AMP-activated protein kinase
(AMPK) [51]. However, β3-integrin silencing reversed
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the effect by increasing anchorage-independent growth
and CD133 marker expression. CD90 is associated with
αVβ3-integrin through its regulation of signal transduction
in astrocytes and neuronal cells [54]. Taken together, this
suggests negative regulatory role of CD90 together with
β3-integrin signaling in the context of CSCs and the EOC
spheroid phenotype.
Spheroids present in malignant ascites can interact with
other cell types to affect their phenotype. For example, an
analysis of cell components in spheroids isolated from the
ascites of 128 patients with stage III ovarian cancer showed
the presence of macrophages in all spheroids [55]. The number of macrophages present with spheroids compared to primary tumors was substantially higher and positively correlated with proliferation in spheroids and negatively with
patient prognosis [55]. Robinson-Smith et al. demonstrated
spheroid implantation in a mouse model of EOC increased
due to inflammation, whereas the loss of peritoneal macrophages reduced metastatic potential, supporting the role of
tumor-associated macrophages (TAMs) in EOC progression
[56]. EOC spheroid cells express intercellular adhesion molecule 1 (ICAM1), a ligand that binds leukocyte-associated
integrin subunits αM and αX. Blockade of this interaction
between EOC cells and TAMs diminishes spheroid formation in both mouse and human in vitro spheroid co-culture
models [55]. TAMs are a source of epidermal growth factor
(EGF), and EGF signaling is critical for EOC cell proliferation to increase VEGF-C and enhance integrin-ICAM1
expression, spheroid formation and migration [55].

Integrins in epithelial‑mesenchymal transition
and EOC cell migration
Carcinoma cells destined for dissemination oftentimes coexpress epithelial and mesenchymal markers, commonly
referred to as epithelial-mesenchymal transition (EMT),
allowing for a cadherin switch [36, 57]. EMT allows ovarian
cancer cells to loosen intercellular adhesions between cells
contributing to the transition of cells from a primary tumor
to shed as single cells or spheroids into the ascites [5, 39].
During this EMT process, EOC cells gain enhanced invasive properties, survive in hypoxic conditions, and spread
through the abdominal cavity by the peritoneal fluid flow
[57, 58]. The decrease in cell–cell adhesion and detachment
of EOC cells from the primary tumor into the peritoneal cavity is mediated through the integrin-mediated upregulation
of matrix metalloproteinases (MMPs) and activation of EMT
[36]. Clustering of collagen-binding integrins α2β1 and
α3β1 on EOC cells leads to the induction of MMP9, which
is capable of E-cadherin ectodomain cleavage and cell–cell
adhesion loosening in an Src kinase-dependent manner
[59]. E-cadherin loss leads to transcriptional upregulation
of fibronectin receptor α5β1 integrin, which is essential
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when spheroids initiate adhesion at a secondary site [60].
Decreased E-cadherin is also accompanied by reductions
in occludins, claudins, epithelial cell adhesion molecule
(EpCAM), α6β4-integrin and cytokines, all of which act to
stabilize tight cell–cell contacts via desmosomes [22]. In a
reciprocal fashion, there are increases in vimentin, fibronectin, N-cadherin, β1- and β3-integrins and matrix metalloproteinases [22]. Forced downregulation of E-cadherin in
EOC cells increases α5-integrin expression through FAK
and ERK1 activities leading to enhanced cell adhesion to
fibronectin [61]. As expected, these EMT-like changes due
to E-cadherin loss promote EOC cell invasive properties
required for metastasis [58].
TGF-β signaling is widely-recognized as one of the most
important pathways required to promote EMT in human
cancers. We demonstrated that TGF-β activity is induced
during ascites-derived EOC spheroid formation and controls increased mesenchymal marker transcript expression, whereas its inhibition dramatically reduces EMT
properties and cell–cell cohesion within spheroids [62].
In breast cancer, Bianchi et al. have shown that β-integrin
subunits associated with αV-integrin are upregulated during
TGF-β-induced EMT, and the specific downregulation of
β5-integrin blocks this effect [63]. Similarly, αVβ8-integrin
mediates latent TGF-β activation and resultant EMT in various cancers contributing to cell migration and growth [64].
The ascites microenvironment within which EOC cells
and spheroids reside may play a critical role in promoting
a partial shift towards their mesenchymal phenotype [46].
When cultured EOC cells are exposed to ascites, αV-integrin
localization moves from focal contact structures to intracellular perinuclear vesicles in IGROV1 cells [46]. Furthermore, the αV-integrin cyclic antagonist cRGDfc peptide
inhibited multicellular aggregate formation by 40% compared to a non-targeting control peptide [46]. Taken together,
these studies suggest that αV-integrin and TGF-β work in
concert to control EMT, cell adhesion and migration, within
the context of EOC spheroids; however, a broader role of
αv-integrin complexes in EOC pathogenesis remains unclear
and further investigation is required.

Integrin‑mediated mesothelial attachment
and migration
When establishing secondary tumors, spheroids attach to
the mesothelium lining through the interactions between
spheroids and surface receptors on the mesothelial layer
[22, 65]. At this point, spheroid cells induce expression of
several integrins that prime the spheroids for attachment to
the mesothelium and underlying ECM proteins [22, 41, 66].
For example, interaction between spheroid cells expressing α5β1-integrin receptor and the mesothelium containing
fibronectin matrix is essential for spheroid adhesion [41].

Clinical & Experimental Metastasis (2022) 39:291–301

Although Casey et al. showed that neutralizing antibodies
against α5β1- and αVβ3-integrins did not affect the binding of EOC cells to the mesothelium, additional studies by
this group and others have shown a partial block in adhesion when inhibitory β1-integrin antibody was administered
[41, 67, 68]. Similarly, inhibition of α3-, α6- and β1-integrin
subunits decrease invasiveness and collagen-binding of
spheroids [36]. As the major receptors for ECM proteins,
integrins are critical regulators of EOC cell adhesion and
invasion at a secondary site.
The final step of EOC metastasis occurs when spheroids
penetrate mesothelial surfaces and degrade the ECM within
the basement membrane underlying the peritoneum, omentum and abdominal organs [69]. Kaur et al. demonstrated
that β3-integrin expression correlates with increased EOC
cell adhesion in vitro and adhesion to mesothelium and
mouse omentum in vivo [70]. However, they also showed
that αVβ3-integrin overexpressing cells inhibited invasion using Matrigel, and β3-integrin blockade resulted in
enhanced invasion in CAOV3 and MONTY1 cells [70].
These latter results were recapitulated in vivo where αVβ3integrin overexpressing cells displayed a 35% decrease in
intra-abdominal metastases and 53% decrease in tumor
weight compared to controls [70]. These results highlight
the potential mechanistic differences involving integrins
between EOC cell adhesion, invasion, and successful secondary tumor establishment.
Integrins function in both cell–cell adhesion and binding
to basement membrane and ligand components [69]. α2- and
β1-integrin subunits contribute to EOC cell adhesion via collagen I facilitating peritoneal attachment and invasion into
the mesothelial monolayers [71]. Several studies have shown
that inhibition of collagen-associated α2β1-integrins leads
to attenuated spheroid disaggregation on artificial ECM
since primary EOC cells adhere to type I collagens preferentially [59, 67, 72]. Furthermore, Davidson et al. showed
high expression of αV- and β1-integrin subunits in malignant cells from peritoneal and pleural effusions collected
from late-stage EOC patients suggesting a potential role in
metastasis [73]. The interaction between vascular cell adhesion molecule 1 (VCAM-1) present on the mesothelium and
α4β1-integrins on EOC cells promotes metastasis and cell
migration in xenograft models [69]. Indeed, this study also
demonstrated that the use of function-blocking antibodies
against either VCAM-1 or α4β1-integrins show promise in
decreasing EOC metastasis [74].
Recent studies suggest that EOC cells may not adhere
directly to mesothelial cells, but rather to underlying connective tissue; this is achieved by disrupting cell–cell junctions, a process called mesothelial cell clearance [75]. Using
highly innovative live-cell imaging techniques, Iwanicki
et al. demonstrated that EOC spheroids use integrin- and
talin-dependent activation of myosin traction force to
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promote mesothelial cell clearance [75]. In this experimental
model, mesothelial cell monolayers were plated on fibronectin-coated polyacrylamide gels to mimic physiologicallyrelevant stiffness of connective tissue. They showed that
OVCA433 spheroids induced mesothelial clearance by the
above mechanisms [75]. As spheroids promote mesothelial
clearance, fibronectin fibrils organized on top of mesothelial
cells are redistributed away from between the mesothelium
and attaching spheroids [75]. Blocking of α5-integrin, talin
1 and non-muscle myosin II abrogated mesothelial displacement, while ectopic expression of α5-integrin increased
myosin-mediated cell spreading, stress fibers, and other
cortical actin contractile structures [75]. Collagen I-associated α2-integrin subunit induced fibril reorganization and
transmitted traction forces to ECM, but spheroids expressing high levels of α2-integrin rather than α5-integrin were
unable to clear the mesothelium [75]. Interestingly, blockade
of another fibronectin receptor αVβ3-integrins did not affect
mesothelial clearance, suggesting these specific receptors do
not have a myosin-contractility roles in EOC metastasis [75].
In a different study, Kokenyesi et al. reported SKOV3 and
OVCAR3 cells were unable to invade a collagen I matrix due
to their inability to disrupt intercellular interactions, highlighting the importance of integrin-mediated actomyosin
contraction to overcome cell–cell attachments [76].
A critical component of tumor invasion is enzymatic degradation of the ECM, which permits cancer cells to penetrate the basement membrane, gain access to the vasculature
and successful formation of secondary tumor growth [40].
Spheroid cell migration using OVCAR5 cells on lamininand collagen IV-coated surfaces showed a modest twofold
change in cell migration over 24 h, whereas spheroids on
fibronectin and collagen I completely disaggregated to form
a monolayer with a ninefold change in surface area [40,
66]. Addition of an inhibitory antibody against β1-integrin
completely eliminated spheroid cell migration on laminin,
fibronectin and type-IV collagen, and a 50% reduction on
type-I collagen [40, 66]. However, these results suggest that
β1-integrin blockade did not prevent initial spheroid attachment, but rather significantly impacted ECM degradation
and spheroid disaggregation of invading foci [40]. Overall,
β1-integrins partially mediate adhesion of EOC spheroid
cells to ECM, but it likely plays a more significant role in
ECM degradation to promote spheroid disaggregation [40,
66].
MMPs are zinc-dependent proteinases that degrade
various ECM components, such as collagens, proteoglycans, gelatins, vitronectin, and fibronectin [77]. EOC cells
that express higher levels of MMP2 and MMP9 possess
increased invasive and metastatic potential [72, 78]. Studies by Kenny et al. demonstrated that contact of EOC cells
with mesothelium induces MMP2 expression at the transcriptional and translational levels [79]. Activated MMP2
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cleaves various ECM components, including vitronectin
and fibronectin, into smaller fragments to improve EOC
cell adhesion to αVβ3- and α5β1-integrin receptors [79].
αVβ3- and α5β1-integrin blocking antibodies inhibited cell
adhesion, however, this effect was abolished when EOC cells
were preincubated with MMP2 antibody [79].
When cells migrate away from the core of an attached
spheroid, cell–cell contacts are reduced while adhesion and
spreading on ECM occurs. Compared to monolayer culture,
MMP2 and MMP9 activities are increased in serum-free
medium collected from spheroid culture [72]. Interestingly,
Shield et al. demonstrated OVHS1 and HEY spheroids have
reduced disaggregation in the presence of α2β1-integrin
with a coordinated reduction in active MMP2 levels [72].
The reciprocal expression of increased α2-integrin and
decreased α6-integrin subunits in OVHS1 and HEY spheroids were also observed.
Furthermore, αVβ6-integrin in EOC is correlated with
increased expression and secretion of high molecular
weight-urokinase-type plasminogen activator (uPA), proMMP2 and pro-MMP9, in tumor-conditioned media [78].
Interestingly, αVβ6-integrin expression is restricted to
metastatic EOC cells with little to no expression in benign
and normal ovarian epithelial cells [78]. Results from this
same study demonstrate that αVβ6-integrin-expressing EOC
cell lines have an enhanced capacity to degrade the basement membrane in a plasminogen-dependent manner since
this effect was completely abolished by inhibition of uPA,
MMP9, or αVβ6-integrins [78].

Integrins as therapeutic targets for EOC
Novel therapies that focus on malignant cells and their
interactions with the tumor microenvironment in EOC have
gained substantial interest due to the complexity of this disease. As described in detail above, integrins are key regulators at various steps in the unique metastatic cascade of
EOC, particularly during the process of spheroid formation
during transit, and for peritoneal invasion where integrinECM interactions are essential during spheroid adhesion and
invasion [36].
Preclinical and clinical studies of integrin antagonists
show promising results to effectively block tumor progression [80]. Integrin inhibitors represent a feasible therapeutic
strategy since the majority of Phase I clinical trials demonstrate that these agents are well-tolerated by patients in
conjunction with cytotoxic chemotherapy or radiotherapy
[13, 36]. The chimeric monoclonal antibody Volociximab
targets α5β1-integrin and has been successful in inhibiting
angiogenesis and impairment of tumor growth [77]. Preclinical data shows that intraperitoneal treatment of SKOV3ip1
xenografted mice with Volociximab reduced tumor burden
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and ascites accumulation by 83% and 97%, respectively [81].
Encouragingly, clinical trials showed that EOC patients with
platinum-resistant disease treated with a weekly administration of Volociximab was well-tolerated [82]. ATN-161
is a non-RGD based synthetic pentapeptide derived from
fibronectin that binds to and blocks both α5β1- and αVβ3integrins [83]. This agent has shown promise using mouse
xenograft models of breast cancer metastasis and it was safe
in patients with stable disease, but has not been tested in
EOC patients yet [84, 85]. Etaracizumab is an anti-human
monoclonal antibody against αVβ3-integrin developed after
encouraging preclinical results showing decreased tumor
burden in SKOV3ip1 and HEYA8 xenograft mouse models [86]. However, clinical trials showed minimal effectiveness as a therapeutic treatment for metastatic disease [83].
Another humanized antibody Intetumumab targeting αVβ3and αVβ5-integrins showed effective inhibition of cancer
cell adhesion and migration of six different uterine serous
papillary carcinoma cell lines in vitro [87]. Phase I clinical trials show that it is safe, it localized to tumors, and it
exhibited some signs of anti-tumor activity, but these early
findings require additional trials [88]. Although promising
results have been seen with anti-integrin αVβ3 antibodies,
results from Kaur et al. suggest that of overexpression of
this integrin complex correlates with a favorable patient outcome; thus, further clinical investigations are required [70].
Several different approaches for targeting integrins may
offer therapeutic potential in the future, however no single
integrin receptor complex inhibition strategy has shown sufficient clinical trials data to progress for further investigation
yet [36]. One major hurdle impeding success may be the
complexity and dynamics of integrin functions implicated in
EOC tumor growth and metastasis (Fig. 2). For instance, the
crucial interaction of EOC cells for adhesion via fibronectin
is not limited to α5β1-integrin, as αVβ3- or α3β1-integrins
can compensate for its loss-of-function [36]. Adding to this
challenge will be the broad intratumor and interpatient heterogeneity in this disease. Insight into the cellular mechanisms
involved in cancer cell survival and progression through
in vitro and in vivo models are critical to the development
of cancer therapy. As such, the complex intratumoral and
interpatient heterogeneity in EOC can be addressed experimentally through the use of patient-derived organoid (PDO)
models that retain many features of primary tumors [89].
This relatively new three-dimensional tumor model will be
important to further address integrin-mediated function on
disease pathogenesis, particularly when compared with the
established evidence using spheroids in suspension.
In conclusion, integrin expression and function are clearly
implicated at numerous steps of EOC metastasis, most notably as spheroid cells in the peritoneal cavity and their subsequent attachment and invasion at secondary sites [90]. As
mediators of EOC metastasis to the mesothelium, the use of
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specific integrin inhibitors alone or in combination could
prove effective in preventing sustained interaction between
EOC cells and mesothelium. Taken together, we foresee that
a combined approach of targeting multiple integrin-associated pathways may be worthy of future exploration in both
experimental and clinical applications.
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